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BACKGROUND
In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosup-
pression, as compared with cyclosporine-based immunosuppression, was associ-
ated with similar patient and graft survival and significantly improved renal func-
tion in kidney-transplant recipients. Here we present the final results from this 
study.
METHODS
We randomly assigned kidney-transplant recipients to a more-intensive belatacept 
regimen, a less-intensive belatacept regimen, or a cyclosporine regimen. Efficacy 
and safety outcomes for all patients who underwent randomization and transplan-
tation were analyzed at year 7 (month 84).
RESULTS
A total of 666 participants were randomly assigned to a study group and under-
went transplantation. Of the 660 patients who were treated, 153 of the 219 patients 
treated with the more-intensive belatacept regimen, 163 of the 226 treated with 
the less-intensive belatacept regimen, and 131 of the 215 treated with the cyclo-
sporine regimen were followed for the full 84-month period; all available data 
were used in the analysis. A 43% reduction in the risk of death or graft loss was 
observed for both the more-intensive and the less-intensive belatacept regimens as 
compared with the cyclosporine regimen (hazard ratio with the more-intensive 
regimen, 0.57; 95% confidence interval [CI], 0.35 to 0.95; P = 0.02; hazard ratio 
with the less-intensive regimen, 0.57; 95% CI, 0.35 to 0.94; P = 0.02), with equal 
contributions from the lower rates of death and graft loss. The mean estimated 
glomerular filtration rate (eGFR) increased over the 7-year period with both be-
latacept regimens but declined with the cyclosporine regimen. The cumulative 
frequencies of serious adverse events at month 84 were similar across treatment 
groups.
CONCLUSIONS
Seven years after transplantation, patient and graft survival and the mean eGFR 
were significantly higher with belatacept (both the more-intensive regimen and the 
less-intensive regimen) than with cyclosporine. (Funded by Bristol-Myers Squibb; 
ClinicalTrials.gov number, NCT00256750.)
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The use of prolonged maintenance immunosuppressive therapy after kidney transplantation has improved the short-
term outcomes,1 but the effect on long-term 
allograft survival is not known.2 Prospective, 
phase 3, randomized studies examining the 
outcomes of immunosuppressive regimens be-
yond 5 years or showing a survival advantage of 
newer immunosuppressive regimens over that 
afforded by regimens containing the calcineurin 
inhibitor cyclosporine are lacking.3-5 Belatacept 
is a selective costimulation blocker that has been 
developed to improve long-term outcomes in 
kidney-transplant recipients by providing effective 
immunosuppression without the toxic effects of 
calcineurin inhibitors.
Current standard-of-care immunosuppressive 
regimens combine calcineurin inhibitors with 
antiproliferative drugs, with or without mainte-
nance glucocorticoids. Calcineurin inhibitor–
based regimens, however, may not adequately 
preserve allograft function,6-8 leading to deterio-
rating kidney function, which is a risk factor for 
death from cardiovascular causes in kidney-
transplant recipients.9-11 The development of 
donor-specific antibodies has also been associat-
ed with negative post-transplantation outcomes, 
including an increased risk of antibody-mediated 
rejection and graft failure.12 The lack of improve-
ment in long-term patient and graft survival is 
multifactorial, but cardiovascular disease, calci-
neurin inhibitor–associated nephrotoxicity, emer-
gence of donor-specific antibodies, and nonad-
herence to treatment are major contributors.1,11,12
Belatacept, a fusion protein composed of the 
Fc fragment of human IgG1 linked to the extra-
cellular domain of cytotoxic T-lymphocyte–asso-
ciated antigen 4 (CTLA-4), selectively inhibits 
T-cell activation through costimulation block-
ade.13-15 Belatacept was approved by the U.S. 
Food and Drug Administration16 and the Euro-
pean Medicines Agency17 in 2011, on the basis, 
in part, of 3-year data from two phase 3 studies: 
the Belatacept Evaluation of Nephroprotection 
and Efficacy as First-line Immunosuppression 
Trial (BENEFIT) and BENEFIT–Extended Crite-
ria Donors (BENEFIT-EXT).18-23 A less-intensive 
 belatacept regimen is approved for use only in 
patients who are positive for Epstein–Barr virus 
(EBV), given the increased risk of post-trans-
plantation lymphoproliferative disorder, predom-
inantly involving the central nervous system, in 
EBV-seronegative patients.16,17 Patients in the 
belatacept trial were not prospectively stratified 
according to EBV status when the study started, 
since no safety signal was identified on the basis 
of EBV-negative serostatus. The decision to restrict 
belatacept for use only in EBV-positive patients 
was based on the findings of the phase 3 trials. 
The present report summarizes the final efficacy 
and safety results up to 7 years (84 months) after 
transplantation in the intention-to-treat popula-
tion of BENEFIT.
Me thods
Study Design and Oversight
The trial design has been published previously.18 
The original study was a 3-year, international, 
randomized, single-blind, parallel-group study 
with an active control. The participants were 
adults who received a kidney transplant from a 
living or deceased donor, with deceased donors 
meeting standard-criteria donor status on the 
basis of age and other benchmarks. Patients 
were randomly assigned (in a 1:1:1 ratio) to a 
more-intensive belatacept-based regimen, a less-
intensive belatacept-based regimen, or a cyclo-
sporine-based regimen for primary immuno-
suppression. All patients received basiliximab 
induction, mycophenolate mofetil, and glucocor-
ticoids. Patients were eligible to continue with 
the assigned therapy beyond 36 months if they 
provided written informed consent and if they 
received the approval of their physician. After 36 
months, patients were required to continue the 
assigned regimen to remain in the study.
The study was conducted in accordance with 
the Declaration of Helsinki. The ethics commit-
tee at each site approved the study protocol. All 
patients provided written informed consent.
The sponsor, Bristol-Myers Squibb, designed 
the study and gathered and analyzed the data in 
collaboration with the study investigators. All 
the authors vouch for the accuracy and complete-
ness of the data and analyses, and the first au-
thor vouches for the fidelity of the study to the 
protocol. A medical writer at CodonMedical, an 
Ashfield company, who was paid by the sponsor, 
wrote the first draft of the manuscript under the 
direction of the authors. No contractual arrange-
ments were in effect to allow the sponsor to 
have sole control of the data or to withhold 
publication of the data.
A Quick Take is 
available at 
NEJM.org 
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Outcome Measures
The primary objective at month 12 was an as-
sessment of the composite end point of patient 
and graft survival, renal function, and the inci-
dence of acute rejection in each belatacept group 
as compared with the cyclosporine group.18 For 
the present analysis, outcomes were evaluated 
from randomization to month 84 (year 7). The 
contributions of the individual components — 
patient survival and graft survival — of the 
composite end point of patient and graft sur-
vival were also determined. Renal function was 
assessed on the basis of the estimated glomeru-
lar filtration rate (eGFR), which was calculated 
with the use of the six-variable Modification of 
Diet in Renal Disease equation.24 Safety out-
comes were expressed as incidence rates per 100 
person-years of exposure to the assigned treat-
ment. The development of donor-specific anti-
bodies was determined centrally by means of 
solid-phase f low cytometry (FLowPRA, One 
Lambda); the HLA class specificity of detected 
antibodies was assessed with the use of the 
LABScreen single-antigen-bead–based assay (One 
Lambda).
Statistical Analysis
In this prospective analysis, we used a log-rank 
test to assess the time to death or graft loss with 
each belatacept regimen as compared with the 
cyclosporine regimen. Kaplan–Meier survival 
curves and event rates are presented. Hazard 
ratios and 95% confidence intervals for death or 
graft loss for the first 60 months and for the 
first 84 months were derived with the use of Cox 
regression; for the calculation of hazard ratios, 
data were censored at month 60 and month 84, 
respectively. Time to death and time to graft 
loss, with censoring of data for patients who 
died, were assessed as sensitivity analyses in or-
der to determine the contribution of each compo-
nent to the composite end point; both statisti-
cal methods were used, without adjustment for 
multiple comparisons. In the analyses of the 
time to death or graft loss, censoring rules 
were as follows: first, if a date of death but no 
date of graft loss was reported for a patient, the 
time to the event was defined as the time from 
transplantation to the date of death; second, if 
a graft-loss date but not a date of death was re-
ported for a patient, the time to the event was 
defined as the time from transplantation to the 
date of graft loss; third, if both a graft-loss date 
and a date of death were reported for a patient, 
the time to the event was defined as the time 
from transplantation to the date of graft loss; 
and fourth, if no date of death or graft-loss date 
was reported, the data were censored at the re-
ported date of the last follow-up assessment. For 
patients treated for up to 7 years, the last follow-
up assessment was at 7 years. For patients who 
discontinued treatment before 7 years and were 
not followed thereafter, censoring occurred on the 
date of the last available follow-up assessment.
The mean eGFR and corresponding confi-
dence intervals were determined from month 1 to 
month 84 with the use of a repeated-measures 
model with an unstructured covariance matrix, 
which takes into account between-patient vari-
ability and the intrapatient correlation of eGFR 
measurements across all time points. This model 
assumed that missing data were missing com-
pletely at random and included treatment, time, 
and a time-by-treatment interaction; no adjust-
ment was made for other potentially confound-
ing covariates. Time was expressed as a categor-
ical variable (in intervals of 3 months up to 
month 36 and intervals of 6 months thereafter). 
A sensitivity analysis was performed in which 
eGFR values that were missing because of death 
or graft loss were imputed as zero. The model 
that was used for the primary analysis was also 
used for this sensitivity analysis but with a 
Toeplitz covariance matrix, which best fit the 
data because the unstructured covariance matrix 
was not converging.
A slope-based model without imputation of 
missing values was also used to determine 
whether there was a difference between the slope 
for each belatacept regimen and the slope for 
cyclosporine, assuming the linearity of the eGFR 
values between months 1 and 84. The difference 
between slopes was tested with the use of a 
contrast statement within the SAS model (SAS 
software, version 9.2; SAS Institute). Time was 
regarded as a continuous variable, treatment as 
a fixed effect, and the intercept and time as ran-
dom effects; no adjustment was made for other 
potentially confounding covariates. A sensitivity 
analysis was performed in which eGFR values 
that were missing because of death or graft loss 
were imputed as zero; the model used for the 
slope analysis without imputation was also used 
for this analysis.
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R esult s
Study Participants
Participants were randomly assigned to a treat-
ment group between January 13, 2006, and June 
14, 2007. Of the 666 patients who underwent 
randomization and transplantation, 660 patients 
were treated; 153 of the 219 patients treated with 
the more-intensive belatacept regimen, 163 of the 
226 treated with the less-intensive belatacept 
regimen, and 131 of the 215 treated with cyclo-
sporine were followed for the full 84-month 
period (Fig. 1), and all available data were ana-
lyzed. The median duration of follow-up for each 
treatment group was 84.0 months (range: more-
intensive belatacept, 0.2 to 84.0 months; less-
intensive belatacept, 0.03 to 84.0 months; and 
cyclosporine, 0.07 to 84.0 months) (see Table S1 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org). Data on 
adherence to medication were collected up to 
month 36 and are summarized in Table S1 in the 
Supplementary Appendix.
Efficacy
On the basis of Kaplan–Meier estimates, rates of 
death or graft loss with more-intensive belata-
cept, less-intensive belatacept, and cyclosporine 
were 7.8%, 8.0%, and 11.4%, respectively, at 
month 36; 10.2%, 9.2%, and 20.2%, respectively, 
at month 60; and 12.7%, 12.8%, and 21.7%, re-
spectively, at month 84 (Table S2 in the Supple-
mentary Appendix). At month 60, the hazard 
ratio for the comparison of more-intensive belata-
cept with cyclosporine was 0.52 (95% confidence 
interval [CI], 0.31 to 0.89; P = 0.01), and the 
hazard ratio for the comparison of less-intensive 
belatacept with cyclosporine was 0.48 (95% CI, 
0.28 to 0.82; P = 0.005). At month 84, the respec-
tive hazard ratios were 0.57 (95% CI, 0.35 to 
0.95; P = 0.02) and 0.57 (95% CI, 0.35 to 0.94; 
P = 0.02) (Fig. 2A).
On the basis of Kaplan−Meier estimates, rates 
of death with more-intensive belatacept, less-
intensive belatacept, and cyclosporine were 4.1%, 
4.5%, and 6.8%, respectively, at month 36; 6.6%, 
5.7%, and 12.7% at month 60; and 9.2%, 8.2%, 
and 14.4% at month 84 (Table S3 in the Supple-
mentary Appendix). At month 60, the hazard ra-
tio for the comparison of more-intensive belata-
cept with cyclosporine was 0.53 (95% CI, 0.27 to 
1.05; P = 0.049), and the hazard ratio for the 
comparison of less-intensive belatacept with 
cyclosporine was 0.47 (95% CI, 0.23 to 0.94; 
P = 0.02). At month 84, the respective hazard ra-
tios were 0.62 (95% CI, 0.33 to 1.14; P = 0.11) and 
0.55 (95% CI, 0.30 to 1.04; P = 0.06) (Fig. 2B). 
Causes of death are summarized in Table S4 in 
the Supplementary Appendix.
Kaplan−Meier estimates for rates of graft loss 
among patients receiving more-intensive belata-
cept, those receiving less-intensive belatacept, 
and those receiving cyclosporine, with censoring 
of data for death, were 4.7%, 4.1%, and 4.6%, 
respectively, at month 36; 4.7%, 4.1%, and 9.8% 
at month 60; and 4.7%, 5.4%, and 9.8% at 
month 84 (Table S5 in the Supplementary Ap-
pendix). At month 60, the hazard ratio for the 
comparison of more-intensive belatacept with 
cyclosporine was 0.56 (95% CI, 0.26 to 1.23; 
P = 0.12), and the hazard ratio for the compari-
son of less-intensive belatacept with cyclospo-
rine was 0.49 (95% CI, 0.22 to 1.09; P = 0.07). At 
month 84, the respective hazard ratios were 0.56 
(95% CI, 0.25 to 1.21; P = 0.12) and 0.59 (95% CI, 
0.28 to 1.25; P = 0.15) (Fig. 2C). Causes of graft 
loss, with censoring of data for death, are sum-
marized in Table S6 in the Supplementary Ap-
pendix. At month 84, the Kaplan–Meier cumula-
tive rates of biopsy-proven acute rejection were 
24.4%, 18.3%, and 11.4% with more-intensive 
belatacept, less-intensive belatacept, and cyclo-
sporine, respectively.
Estimated Glomerular Filtration Rate
The mean eGFR increased during the first 7 years 
with both belatacept-based regimens but declined 
with the cyclosporine-based regimen (Fig. 3). At 
months 12, 36, 60, and 84, the mean eGFR val-
ues were 67.0, 68.9, 70.2, and 70.4 ml per minute 
per 1.73 m2 of body-surface area, respectively, 
with more-intensive belatacept and 66.0, 68.9, 
70.3, and 72.1 ml per minute per 1.73 m2 with 
less-intensive belatacept. The corresponding val-
ues for cyclosporine were 52.5, 48.6, 46.8, and 
44.9 ml per minute per 1.73 m2. The estimated 
differences in the eGFR significantly favored each 
belatacept regimen over cyclosporine (P<0.001 for 
the overall treatment effect of each belatacept 
regimen).
The slope-based analysis of the change from 
month 1 to month 84 showed that patients ran-
domly assigned to the more-intensive belatacept 
regimen had a gain in the mean eGFR of 1.30 ml 
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per minute per 1.73 m2 per year (95% CI, 0.83 
to 1.77) and those assigned to the less-intensive 
regimen had a gain of 1.39 ml per minute per 
1.73 m2 per year (95% CI, 0.93 to 1.84). Over the 
same period, patients randomly assigned to cyclo-
sporine had a decline in the mean eGFR (−1.04 ml 
per minute per 1.73 m2 per year; 95% CI, −1.53 to 
−0.54). The eGFR slopes diverged significantly be-
tween belatacept and cyclosporine over time. The 
treatment-by-time interaction effect derived from 
the mixed-effects model significantly favored each 
belatacept regimen over cyclosporine (P<0.001).
Figure 1. Number of Patients Who Were Enrolled, Underwent Randomization, and Completed the Study.
Patients who could be evaluated were those who were followed for at least 84 months or who had died or had graft 
loss by month 84. LI denotes less intensive, LTE long-term extension, and MI more intensive.
666 Underwent randomization
738 Patients were enrolled
219 Underwent transplantation 221 Underwent transplantation226 Underwent transplantation
219 Were treated 215 Were treated226 Were treated
91 Discontinued study
39 Were ineligible for or declined 
 LTE
14 Withdrew consent
13 Had adverse event
13 Died
4 Were lost to follow-up
2 Were pregnant
1 Had poor adherence or was
nonadherent
5 Had other reason
123 Discontinued study




12 Had adverse event
8 Were lost to follow-up
6 Had lack of efficacy
4 Had poor adherence or were
nonadherent
1 Had administrative reason
6 Had other reason
90 Discontinued study
34 Were ineligible for or declined 
LTE
20 Withdrew consent
11 Had adverse event
11 Died
4 Were lost to follow-up
3 Had lack of efficacy
1 Was pregnant
1 Had poor adherence or was
nonadherent
1 Had administrative reason
4 Had other reason
128 Completed 84-mo study 92 Completed 84-mo study136 Completed 84-mo study
153 Could be evaluated at 84 mo 131 Could be evaluated at 84 mo163 Could be evaluated at 84 mo
219 Were assigned to belatacept MI
Mo 0–3: 10 mg/kg on days 1 and 5 
and at wk 2, 4, 6, 8, 10, and 12
Mo 4–6: 10 mg/kg at wk 16, 20, 
and 24
Beyond mo 6: 5 mg/kg every 4 wk
226 Were assigned to belatacept LI
Mo 0–1: 10 mg/kg on days 1 and 5 
and at wk 2 and 4
Mo 2–3: 10 mg/kg at wk 8 and 12
Beyond mo 3: 5 mg/kg every 4 wk
221 Were assigned to cyclosporine
Initial daily dose: 4–10 mg/kg
Mo 0–1: dose adjusted to
150–300 ng/ml
Beyond mo 1: dose adjusted to
100–250 ng/ml
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Belatacept MI vs. cyclosporine: hazard ratio for death or graft loss, 
0.57 (95% CI, 0.35–0.95); P=0.02
Belatacept LI vs. cyclosporine: hazard ratio for death or graft loss,
0.57 (95% CI, 0.35–0.94); P=0.02 
Belatacept MI vs. cyclosporine: hazard ratio for death,
0.62 (95% CI, 0.33–1.14); P=0.11
Belatacept LI vs. cyclosporine: hazard ratio for death,
0.55 (95% CI, 0.30–1.04); P=0.06
Belatacept MI vs. cyclosporine: hazard ratio for death-censored graft loss,
0.56 (95% CI, 0.25–1.21); P=0.12
Belatacept LI vs. cyclosporine: hazard ratio for death-censored graft loss,
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For the analysis in which eGFR values that 
were missing because of death or graft loss were 
imputed as zero, the mean eGFR values at 
months 12, 36, 60, and 84 were 64.3, 64.8, 63.9, 
and 62.0 ml per minute per 1.73 m2, respective-
ly, with the more-intensive belatacept regimen 
and 63.8, 65.2, 65.2, and 63.3 ml per minute 
per 1.73 m2 with the less-intensive regimen. The 
corresponding values for cyclosporine were 49.8, 
44.3, 39.1, and 36.6 ml per minute per 1.73 m2. 
With imputation of missing values, differences 
in the eGFR remained significantly in favor of 
belatacept (P<0.001 for the overall treatment ef-
fect of each belatacept regimen vs. cyclosporine). 
Results of the slope-based analysis with imputa-
tion showed a slight increase in the mean eGFR 
from month 1 to month 84 for patients randomly 
assigned to the more-intensive belatacept regi-
men (0.20 ml per minute per 1.73 m2 per year; 
95% CI, −0.38 to 0.78) and those assigned to the 
less-intensive regimen (0.38 ml per minute per 
1.73 m2 per year; 95% CI, −0.18 to 0.95), where-
as patients randomly assigned to cyclosporine 
had a decline in the mean eGFR (−1.92 ml per 
minute per 1.73 m2 per year; 95% CI, −2.51 to 
−1.32). With imputation of missing values, the 
treatment-by-time interaction effect remained 
significantly in favor of each belatacept regimen 
(P<0.001).
Safety
At month 84, the cumulative frequencies of seri-
ous adverse events for the more-intensive and 
less-intensive belatacept regimens and for cyclo-
sporine were 70.8%, 68.6%, and 76.0%, respec-
tively. Serious infections were the most common 
adverse events in each treatment group. The cu-
mulative incidence rates of serious infections 
were 10.6, 10.7, and 13.3 events per 100 person-
years of treatment exposure up to month 84 for 
patients randomly assigned to the more-inten-
sive belatacept regimen, those assigned to the 
less-intensive regimen, and those assigned to 
cyclosporine, respectively (Table 1).
The cumulative incidence rates for cancers 
were 2.1, 1.8, and 2.6 per 100 person-years of 
exposure with the more-intensive belatacept 
regimen, the less-intensive regimen, and cyclo-
sporine, respectively (Table 1, and Table S7 in 
the Supplementary Appendix). All but 1 of the 
Figure 3. Glomerular Filtration Rate over the Period from Month 1 to Month 84.
The estimated glomerular filtration rate (eGFR) was determined by repeated-measures modeling, with time as a cat-





























Figure 2 (facing page). Kaplan–Meier Curves for Patient 
and Graft Survival.
Panel A shows the Kaplan−Meier curve for the com-
posite end point of patient and graft survival. Panel B 
shows the Kaplan−Meier curve for the individual con-
tribution of patient survival. Panel C shows the Kaplan−
Meier curve for the individual contribution of graft sur-
vival, with censoring of data for patients who died.
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cases of post-transplantation lymphoprolifera-
tive disorder occurred in the first 24 months. 
Among patients known to be EBV-positive before 
transplantation, 1 case of lymphoproliferative 
disorder, occurring between 12 and 24 months 
after transplantation, was reported in the group 
assigned to the more-intensive belatacept regi-
men (incidence rate, 0.1 cases per 100 person-
years); 2 cases, occurring during the first 12 
months after transplantation, were reported in 
the group assigned to the less-intensive belata-
cept regimen (incidence rate, 0.2 cases per 100 
person-years); and 1 case, occurring between 
60 and 72 months after transplantation, was 
reported in the cyclosporine group (incidence 
rate, 0.1 cases per 100 person-years).
Among EBV-negative patients, 2 cases of lym-
phoproliferative disorder, 1 occurring during the 
first 12 months after transplantation and 1 oc-
curring between 12 and 24 months after trans-
plantation, were reported in the group assigned 
to the more-intensive belatacept regimen (inci-
dence rate, 1.6 cases per 100 person-years), and 
1 case, occurring during the first 12 months after 
transplantation, was reported in the cyclosporine 
group (incidence rate, 0.6 cases per 100 person-
years). Post-transplantation lymphoproliferative 
disorder did not occur in any of the EBV-negative 
patients who were randomly assigned to the less-
intensive belatacept regimen.
Donor-Specific Antibodies
The absolute proportion of patients in whom 
donor-specific antibodies developed by year 7 is 
shown in Figure S1 in the Supplementary Appen-
dix according to treatment group. The Kaplan−
Meier cumulative rates for the development of 










no. of events/100 person-yr
Serious infections 10.6 10.7 13.3
Urinary tract infection 1.9 2.0 3.1
Cytomegalovirus infection 1.4 1.1 0.8
Pneumonia 0.7 1.1 1.4
Pyelonephritis 0.7 0.7 0.9
Sepsis 0.8 0.5 0.8
Gastroenteritis 0.7 0.3 0.7
Acute pyelonephritis 0.5 0.3 0.2
Upper respiratory tract infection 0.1 0.2 0.5
Serious gastrointestinal disorders 3.9 2.2 3.8
Serious general disorders and administration-site conditions 2.5 2.3 2.7
Serious cardiac disorders 2.0 1.4 2.2
Serious vascular disorders 1.8 1.5 2.9
Serious blood and lymphatic system disorders 1.6 1.0 1.6
Serious hepatobiliary disorders 0.5 0.3 0.7
Serious endocrine disorders 0.2 0.3 0.5
Cancer of any grade 2.1 1.8 2.6
*  Only events occurring at an adjusted rate of 2% or more of patients in any treatment group are reported. Event rates 
have been adjusted for the duration of treatment exposure (expressed in person-years). For serious infections and can-
cer of any grade, treatment exposure was calculated from the randomization date to the date of the event, the date of 
the last follow-up assessment, or month 84, whichever was earliest. For all other events, treatment exposure was calcu-
lated from the randomization date to the date of the event, the date of the last dose of study medication plus 56 days, 
or month 84, whichever was earliest. Infections are classified according to the preferred terms in the Medical Dictionary 
for Regulatory Activities.
Table 1. Cumulative Incidence Rates of Selected Adverse Events.*
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84 were 1.2%, 1.9%, and 1.9%, respectively, with 
the more-intensive belatacept regimen and 3.4%, 
4.6%, and 4.6% with the less-intensive regimen. 
The corresponding values for cyclosporine were 
8.7%, 16.2%, and 17.8%. The Kaplan−Meier 
cumulative rate for the development of donor-
specific antibodies was significantly lower with 
each belatacept regimen than with cyclospo-
rine (P<0.001). Information on specific antibody 
classes is provided in Figure S1 in the Supple-
mentary Appendix.
Discussion
In the present study, patients randomly assigned 
to either a more-intensive or a less-intensive belata-
cept regimen had a 43% reduction in the risk of 
death or graft loss at 7 years, as compared with 
patients randomly assigned to cyclosporine. The 
treatment effect was similar for each component 
of the composite end point (time to death and 
time to graft loss). The reduction in the risk of 
death at 7 years was 38% with the more-inten-
sive belatacept regimen and 45% with the less-
intensive regimen as compared with cyclospo-
rine. The corresponding values for the reduction 
in the risk of graft loss, with censoring of data 
for patients who died, were 44% and 41%. The 
difference in patient and graft survival between 
belatacept-based and cyclosporine-based immu-
nosuppression was both statistically and clini-
cally significant.
Results from the 7-year analysis of the present 
study contrast with those from the 7-year analysis 
of BENEFIT-EXT, in which recipients of kidneys 
obtained from deceased donors meeting expanded-
criteria status (i.e., older age and more coexist-
ing conditions than standard-criteria donors) 
were also randomly assigned to receive treat-
ment with the more-intensive belatacept regimen, 
the less-intensive regimen, or cyclosporine.19 
An analysis of the study data of BENEFIT-EXT at 
7 years after transplantation19,21,23 showed that 
the rates of death and graft loss with the belata-
cept-based regimens were similar to the rates 
with the cyclosporine-based regimen.25 The par-
ticipants in BENEFIT had several advantages over 
the participants in BENEFIT-EXT. In addition to 
receiving healthier kidneys (i.e., kidneys from 
living donors or kidneys obtained from stan-
dard-criteria deceased donors), the BENEFIT 
participants were younger overall (mean age, 
43.2 years vs. 56.2 years), as were their donors 
(mean age, 40.2 years vs. 43.2 years); also, the 
transplant recipients in the present study had 
fewer coexisting conditions.18,19 These covariates 
may have contributed to the different outcomes 
of the two studies. Notably, a post hoc analysis 
of BENEFIT-EXT data showed a 41% reduction in 
the risk of death, graft loss, or a mean eGFR 
that was less than 30 ml per minute per 1.73 m2 
7 years after transplantation among patients 
randomly assigned to the more-intensive or less-
intensive belatacept regimen as compared with 
those assigned to cyclosporine (Fig. S2 in the 
Supplementary Appendix). We believe this find-
ing is important because an eGFR value of less 
than 30 ml per minute per 1.73 m2 is equivalent 
to stage 4 or higher chronic kidney disease, a 
point at which it is apparent that some patients 
(if they have further progression) will need main-
tenance dialysis.
In this phase 3 randomized trial, the clini-
cally and statistically significant improvements 
in renal function that were observed with belata-
cept as compared with cyclosporine at earlier 
time points18,20,22 were sustained at 7 years. Rates 
of acute rejection were similar to those in previ-
ous reports,18,20,22 with few cases occurring after 
36 months (no case of acute rejection with more-
intensive belatacept, one case with less-intensive 
belatacept, and two cases with cyclosporine).20,22 
The long-term safety profile of belatacept was 
consistent with that described previously.18,20,22 
Most cases of post-transplantation lymphopro-
liferative disorder occurred during the first 24 
months,18,20,22 a finding that is consistent with 
the findings in kidney-transplant recipients treat-
ed with calcineurin inhibitor–based immuno-
suppressive regimens.26-28
The development of donor-specific antibodies 
can lead to allograft failure.29 Donor-specific 
antibodies are estimated to develop in 11% of 
patients during the year after kidney transplan-
tation and in 20% of patients by 5 years after 
transplantation.29 In our study, the cumulative 
event rates for the development of donor-specific 
antibodies at year 7 were significantly lower 
with both belatacept-based regimens than with 
the cyclosporine-based regimen, a finding that 
supports earlier analyses of the data from this 
trial.18,20 Class 1 donor-specific antibodies typical-
ly develop within 6 months after transplantation 
and are associated with a better prognosis than 
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class II antibodies.30 The frequency of class II 
donor-specific antibodies in our study was lower 
with both belatacept regimens than with cyclo-
sporine. This finding is consistent with the ef-
fect of costimulation blockade in experimental 
transplantation.31
One limitation of our trial was that we did 
not compare belatacept with tacrolimus, the cur-
rent standard-of-care calcineurin inhibitor. How-
ever, patient and graft survival outcomes with 
contemporary tacrolimus-based regimens are 
similar to those observed with cyclosporine-
based regimens.6,32-34
Another limitation is that data for patients 
who did not have an event were censored at the 
last follow-up assessment, which was earlier than 
year 7 for patients who discontinued the study. 
However, in each treatment group, patient re-
tention was high, with a prolonged median 
duration of follow-up. Adherence to the study 
medication (not a primary focus of the study) 
was not directly assessed beyond month 36. We 
expected that adherence would differ for the two 
types of study medication, since cyclosporine 
was administered orally by the patient at home 
and belatacept was administered intravenously 
under the supervision of a health care provider.
We assessed efficacy and safety outcomes in 
kidney-transplant recipients who were treated 
with maintenance immunosuppression beyond 
5 years; other studies of immunosuppressive 
regimens have reported outcomes up to 5 years 
after kidney transplantation.5,35-39 In our study, 
the risk of death or graft loss at year 7 was sig-
nificantly lower for belatacept-treated patients 
than for cyclosporine-treated patients; this result 
was made more notable by the fact that the sur-
vival benefit emerged as early as 5 years after 
transplantation.
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